anti-CD160 Molecule (CD160) Antibodies

Mouse (Murine) CD160 Molecule (CD160) interaction partners

1. CD160 may represent a suitable target for immune intervention in the setting of transplantation to modulate allogeneic cytotoxic responses.

2. CD160 functionally controls cytokine production by natural killer cells.

3. Report additive effects of IL-22 and CD160 in mediating the pro-inflammatory and pro-survival aspects of the host mucosal response in Clostridium difficile infection.

4. During chronic infection the number of CD4(+) T cells expressing programmed death-1 and CD160 were greater over the time-course study than the other CD4(+) T-cell inhibitory ligands.

5. CD160 signaling is particularly important in CD28-independent effector/memory CD8(+) alloreactive T cell activation in vivo and therefore may serve as a novel target for prevention of allograft rejection.

6. soluble CD160, produced by mast cells, may have a role in T-cell-mast cell interactions in vivo

7. Knockout Mice BALB C Mice C3H Mice F344 Rats K562 Cells Cultured Cells

8. CD160 is expressed on the majority of CD8(+) memory T cells as well as recently activated CD8(+) T cells

Human CD160 Molecule (CD160) interaction partners

1. CD160 and CD200 are expressed in B cells in chronic lymphocytic leukemia and are absent in other mature B-cell neoplasms.

2. Data suggest that CD160 may become a useful marker in the clinical diagnosis and prognosis of chronic lymphocytic leukemia.

3. elevated CD160 expression on natural killer (NK) cells plays an important role in NK cell loss in atherosclerosis.

4. CD160-expressing human NK cells are costimulated by HVEM expressed in the environment to enhance cytolytic function and cytokine production.

5. analysis of how NK1 receptor Gs versus Gq proteins and beta-arrestin signaling is determined by interactions in the water hydrogen bond network

6. identified 13 ADCC-activated genes. Six gene expression assays including 8 of the 13 genes (CCL3, CCL4/CCL4L1/CCL4L2, CD160, IFNG, NR4A3 and XCL1/XCL2) were analyzed in 127 kidney biopsies

7. CD160FCA offers a simple assay for minimal residual disease detection in CLL and gives prognostic information across different CLL risk groups.

8. report high frequencies of CD160 on CD8+ T cells, with significantly higher levels on HTLV-1 specific CD8+ T cells

9. A population of CD4+ CD160+ T lymphocytes was identified in circulating cutaneous T cells.

10. Antibodies targeting CD160-GPI complement the blockade of PD-1 to enhance HIV-specific T-cell responses and warrant further investigation in the development of novel immunotherapeutic approaches.

11. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction.

12. results indicate that CD160+ lymphocytes could be able to play a role in the maintenance of healthy pregnancy

13. circulating NK cells from PNH patients exhibit a self-MHC class I molecule reactive effector function, which could be mediated through the recruitment of CD160-TM receptor.

14. The results of a mutagenesis study of HVEM suggest that the CD160 binding region on HVEM was slightly different from, but overlapped with, the BTLA binding site.

15. demonstrated CD160 expression in 98% of chronic lymphocytic leukemia cases, 100% of hairy cell leukemia cases, 15% of mantle cell lymphoma in the leukemic phase, and 16% of other B-cell lymphoproliferative disorders

16. A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.

17. soluble CD160, produced by mast cells, may have a role in T-cell-mast cell interactions in vivo

18. Activation through CD160 leads to PI3K-dependent chronic lymphocytic leukemia protection from spontaneous in vitro apoptosis, as well as cellular activation with cell cycle progression and cytokine production.

19. BY55 functions as a co-receptor in TCR signal transduction of a human cytotoxic effector T lymphocyte subset lacking CD28 expression

20. CD94-expressing cells with cytolytic activity against the recipient's leukemic and tumor cells without enhancement of alloresponse might be able to be expanded from donor G-PBMCs.